

Association of Coloproctology of Great Britain & Ireland (ACPGBI): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) – Diagnosis, Investigations and Screening

Chris Cunningham*, Kai Leong†, Susan Clark‡, Andrew Plumb§, Stuart Taylor§, Ian Geh¶, Sharad Karandikar** and Brendan Moran††

*John Radcliffe Hospital, Oxford, UK, †University Hospitals Coventry and Warwickshire, Coventry, UK, ‡Imperial College and St Mark's Hospital, Harrow, London, UK, §University College London Hospital, London, UK, ¶Queen Elizabeth Hospital, Birmingham, UK, **Birmingham Heartlands Hospital, Birmingham, UK, and ††Basingstoke & North Hampshire Hospital, Basingstoke, UK

2 Diagnosis, Investigations and Screening

2.1 Initial diagnosis

- 2.1.1 Process of referral and investigation
- 2.1.2 Choice of investigations
- 2.1.3 Quality of investigations
- 2.1.4 Diagnosis of colorectal cancer

2.2 Staging of Colorectal Cancer

- 2.2.1 Assessment of local disease
- 2.2.2 Metastatic disease
- 2.2.3 Synchronous colonic disease

2.3 Colorectal Cancer Screening

2.3.1 Screening for average risk population

- 2.3.1.1 NHS Bowel Cancer Screening Program (BCSP)
- 2.3.1.2 NHS Bowel Scope Program

2.3.2 Screening for at risk population

- 2.3.2.1 Risk stratification according to family history
- 2.3.2.2 Lynch syndrome
- 2.3.2.3 Familial adenomatous polyposis (FAP)
- 2.3.2.4 MYH-associated polyposis
- 2.3.2.5 Serrated polyposis
- 2.3.2.6 Peutz-Jeghers syndrome
- 2.3.2.7 Juvenile polyposis

2 Diagnosis, Investigations and Screening

Investigation of colorectal cancer may be considered in three distinct groups:

- a) Initial diagnosis
- b) Staging of colorectal cancer
- c) Surveillance following completion of treatment

2.1 Initial diagnosis

2.1.1 Process of referral and investigation

Concern over a diagnosis of colorectal cancer should prompt urgent referral, in most cases within general practice through a 'two week wait rule'. Criteria for two-week wait referral (National Institute for Health and Clinical Excellence, 2015) should be satisfied and in many institutions, patients are offered a 'direct to test service'. Initial investigations are planned on the basis of presenting symptoms (anaemia, change in bowel habit, rectal or abdominal mass), age and co-morbidity, as well as available local expertise and resources. A typical investigation algorithm is shown in Table 2.1. Patients presenting via a non-urgent route should also be investigated along

Correspondence to: Mr Sharad Karandikar, Birmingham Heartlands Hospital, Birmingham, UK.

E-mail: sharad.karandikar@heartofengland.nhs.uk

similar lines. The NICE guidance (NG 12) for suspected colorectal cancer (National Institute for Health and Clinical Excellence, 2015) recommends using faecal occult blood testing for a subset of patients without rectal bleeding. This remains contentious due to equivocal evidence in symptomatic patients. Its practical implementation remains challenging in most regions.

Patients with suspected colorectal cancer should be referred urgently to a team specializing in the management of colorectal cancer.

Recommendation grade D

2.1.2 Choice of investigations

The recent UK Special Interest Group in Gastrointestinal and Abdominal Radiology (SIGGAR) trials (Atkin *et al.*, 2013; Halligan *et al.*, 2013) provides level I evidence on the choice for whole colon imaging in patients with symptoms suggestive of colorectal cancer. The trial comprised a composite single endpoint incorporating:

- 1 CT colonography (CTC) *vs* double contrast barium enema (DCBE), with detection rates of cancer and large polyps (≥ 1 cm).
- 2 CTC *vs* optical colonoscopy (OC), powered to measure the requirement for additional colonic tests following the randomized investigation. The rationale is

Table 2.1 Investigation algorithm for suspected colorectal cancer.

Symptom	Age	2WW Indication	Please tick*	Direct to test	Results
Change in bowel habit	Over 55	Looser and/or more frequent stools , persistently for more than 6 weeks without rectal bleeding	Colonoscopy Fit for bowel prep!* Y { } N { }	Colonoscopy Fit for bowel prep!* Y { } N { }	Positive test (cancer) – direct referral to MDT via colorectal nurse specialists <i>Or to other MDT if non-GI cancer e.g. ovarian</i> Negative test (no major pathology) – Once cancer has been excluded, patient will be referred back to GP e.g. coeliac disease, gallstones, hernias etc. Only in exceptional circumstances where immediate onward referral is deemed clinically necessary will onward referral be made by the secondary care clinician see OTHER below:
Rectal bleed	Over 40	Change in bowel habit – rectal bleeding with a change in bowel habit to looser and/or more frequent stools persistently for 6 weeks	Colonoscopy Fit for bowel prep!* Y { } N { }	Colonoscopy Fit for bowel prep!* Y { } N { }	Other - Any condition detected on investigation that poses <i>imminent</i> danger of deterioration or serious harm to the patient e.g. AAA >5 cm, Inflammatory bowel disease, decompensated cirrhosis, colonic polyyp ≥1 cm, will be referred directly to the appropriate service.
Over 55		No change in bowel habit Rectal bleeding persistently for >6 weeks without a change in bowel habit & without anal symptoms	Flexible sigmoidoscopy	Flexible sigmoidoscopy	
Mass	All ages	Rectal – A definite palpable rectal (not pelvic) mass	Flexible sigmoidoscopy	Flexible sigmoidoscopy	
All ages		Abdominal – A definite palpable abdominal mass	CT colonography or colonoscopy	CT colonography or colonoscopy	
Anaemia	All ages	Men – of any age with unexplained iron deficiency 110 g/l or below	+ OGD	+ OGD	
All ages		Women – non-menstruating women with unexplained iron deficiency anaemia 100 g/l or below.	CT colonography or colonoscopy	CT colonography or colonoscopy	
Any of above	>75 years	As above (please tick) BUT aged >75 years or symptoms not covered in above	+ OGD	+ OGD	
			2WW Outpatient clinic	2WW Outpatient clinic	Clinic then Direct-to-Test and as above

that subsequent OC with biopsy will usually be required for CTC-suspected cancer or significant polyp, and that any benefit in avoiding an endoscopic procedure would be cancelled out if a CTC precipitates a large number of subsequent unnecessary colonoscopies. Conversely, OC is more often suboptimal, limited or incomplete in the more elderly symptomatic population, which may lead to further colonic investigations.

The principal finding was that CTC detected significantly more cancers and large polyps than DCBE (7.3% *vs* 5.6%; $P = 0.039$). Patients randomized to CTC were diagnosed with fewer post-test colorectal cancers than DCBE during a 3-year follow up period (3/45 *vs* 12/85). No significant difference was found in detection rates between CTC and OC (10.7% *vs* 11.4%) but CTC generated more colonic investigations than OC (relative risk 3.65). Post-test colorectal cancers during 3-year follow up were 1/29 for CTC and 0/55 for OC, confirming prior meta-analysis suggesting no significant difference in sensitivity of the two tests for colorectal cancer (Pickhardt *et al.*, 2011).

Patients with suspected colorectal cancer should be offered either optical colonoscopy or CT colonography.

Recommendation grade A

CT colonography should replace double contrast barium enema.

Recommendation grade A

2.1.3 Quality of investigations

Regardless of whether OC or CTC is used, certain levels of Quality Assurance should be achieved by these investigations.

- Colonoscopy

Colonoscopy should be performed by an experienced colonoscopist, or a colonoscopist who has been certified by the Joint Advisory Group (JAG), or by trainees supervised by one of the above. National quality and safety standards for endoscopy have been set by the Department of Health using a Global Rating Scale (GRS) (www.grs.nhs.uk) and by the British Society for Gastroenterology (www.BSG.org.uk). The quality and safety indicators underpin the respective items using GRS.

- CT Colonography (CTC)

There are several international consensus recommendations regarding acquisition of CTC images (Burling, 2010; McFarland *et al.*, 2009; Neri *et al.*, 2013). The examination may be performed following full purgative bowel preparation and administration of a faecal tagging

agent (oral contrast medium administered several hours prior to the investigation). Some faecal tagging agents such as sodium amidotrizoate/meglumine amidotrizoate (Gastrografin) also have a laxative effect and can be used as a combined cleansing/tagging agent. Although some oral faecal tagging agents have a laxative effect, others do not, and in particularly frail patients a combination of dietary manipulation and non-laxative faecal tagging (such as low-dose iso-osmolar iodinated contrast media, or certain barium sulphate preparations) may achieve adequate image quality to exclude clinically relevant neoplasia. In all cases (with or without purgation), faecal tagging is now regarded as mandatory when performing CTC.

Mechanical insufflation with CO₂ reduces patient discomfort and improves colonic distension, when compared with room air. Intravenous antispasmodic, typically hyoscine butylbromide (Buscopan), also improves distension and may reduce pain. The use of intravenous contrast medium is not essential for colonic lesion detection, but may be an efficient strategy in patients in whom the pre-test probability of either colorectal cancer or important extracolonic pathology is high, and is invariably given when whole colon imaging and staging is required following detection of a cancer where OC failed to evaluate the proximal colon.

All reporting radiologists must meet the recommended standards for competency, and be actively involved in audit of their practice and performance (British Society of Gastrointestinal and Abdominal Radiology (BSGAR), The Royal College of Radiologists, 2014). There are specific stipulations for radiologists involved in the National Bowel Cancer Screening Program (NHS Bowel Cancer Screening Programme, 2012).

Radiological and endoscopic investigations should meet national standards and be subjected to regular Quality Assurance.

Recommendation grade C

2.1.4 Diagnosis of colorectal cancer

Colon cancer should ideally be confirmed histologically, but when a lesion with high probability of malignancy has been detected by CTC, histology prior to surgery is not essential if the segment cannot be reached endoscopically. Conversely, histological confirmation of malignancy should be considered mandatory in all rectal cancers when surgery might result in either a permanent stoma or an ultra-low anterior resection, or when neoadjuvant therapy is being considered. Exception to this may be a large endoluminal lesion where biopsies have been inconclusive and the lesion is not amenable to endoscopic surgery.

Preoperative histological confirmation of colonic cancer is desirable but not essential in cases with high probability of malignancy based on clinical presentation and optimal imaging.

Recommendation grade D

Pre-treatment histological confirmation of rectal cancer is considered essential. Exceptions should be rare and are usually large lesions not amenable to endoscopic removal and inconclusive biopsies.

Recommendation grade D

2.2 Staging of Colorectal Cancer

Staging investigations for colorectal cancer should address three areas:

- a) Assessment of local disease
- b) Metastatic disease
- c) Synchronous colonic disease

2.2.1 Assessment of local disease

Local extent of colonic disease is assessed by abdominal and pelvic computed tomography (CT) to provide information on extent of spread in relation to the bowel wall and adjacent organs. This is essential to the planning of surgery (e.g. non-anatomical resection) and to allow consideration of neoadjuvant therapy when the disease is locally very advanced or unresectable.

CT has limited ability to differentiate the individual layers of the bowel wall, making the distinction between T1 and T2 disease challenging. Although certain tumour morphology features seen on CT colonography, namely an arc-shaped or trapezoidal tumour configuration, may suggest T1 or T2 status, these are yet to be validated in a prospective, multicentre setting. Similarly, the distinction between T3 and T4 disease can be challenging because the latter may be contingent only on sub-millimetre spread through the serosa for peritonealised colon (T4a by TNM 7th edition; T4b by TNM 5th edition). Conversely, because of the naturally high contrast at CT between the bowel wall and the adjacent fat, T3 disease can usually be discriminated from earlier-stage lesions, with one meta-analysis suggesting a 86% sensitivity for T3 disease (Dighe *et al.*, 2010). Furthermore, CT provides potentially useful preoperative prognostic information; tumours can be reliably split into 'low-risk' and 'high-risk' subgroups depending on depth of transmural spread and local lymph node status (Smith *et al.*, 2007). However, at present there is insufficient evidence to recommend triage of higher risk patients for neoadjuvant treatment on these grounds alone, pending the results of ongoing clinical trials such as FOxTROT (EudraCT 2007-001987-55). FOxTROT will also provide

information on the accuracy of CT in the straight to surgery arm (FoxTrot Collaborative Group, 2012).

Lymph node staging is more challenging, although in most cases involved nodes lie along the local vascular pedicle, which is removed with the primary. Meta-analysis suggests that CT is approximately 70% sensitive for the detection of nodal involvement for colonic cancers (Dighe *et al.*, 2010), similar to prior meta-analysis for rectal cancers.

Magnetic resonance imaging (MRI), with few exceptions such as patients with contra-indications to MRI or unwilling due to phobia, is recommended for local staging of rectal cancers, particularly to determine the risk of the circumferential margin (CRM) being involved or threatened by tumour. The ability of MRI to predict a clear (>1 mm) CRM in rectal cancer is very good (>90%) (MERCURY Study Group, 2006). However, staging of lymph nodes is less accurate.

Cancers of the lower third of the rectum are defined on MRI as an adenocarcinoma with its lower edge, at or below the level of origin of the levator muscle on the pelvic side-wall (Moran 2014). Patients with low rectal cancers have generally worse outcomes in terms of curative (R0) resection, local recurrence and overall survival compared to mid and upper rectal cancers. Specific management issues have been identified and addressed through the LOREC program, in order to try to improve outcomes in this group.

Rectal cancer requires specifically tailored locoregional staging since this affects the feasibility and timing of radical surgery, and this will be discussed further in Chapter 4.

Since introduction of the UK NHS Bowel Cancer Screening Program, increasing numbers of early colon and rectal cancers are being diagnosed. Suspected early stage rectal cancers should be assessed with endorectal ultrasound for more accurate local staging if considering the patient for an organ preserving approach. A Significant Polyp Early Colorectal Cancer (SPECC) Program is currently underway to improve definition, recognition, documentation, strategic planning and treatment of these lesions (PelicanCancer.org.uk).

2.2.2 Metastatic disease

Colorectal cancers commonly metastasize to the liver, lungs and peritoneum. Routine staging by CT chest, abdomen and pelvis provides adequate staging in most cases. Further characterization of equivocal liver lesions may be assisted by MRI. 18-Fluorodeoxyglucose positron emission tomography/CT (18-FDG PET/CT) may be used to investigate suspicious lesions seen on CT or MRI. In addition, PET/CT provides valuable assessment to help exclude occult metastatic disease in

patients being considered for non-anatomical resection of locally advanced cancers or surgical management of liver and lung metastases, to facilitate appropriate patient selection aiming to reduce futile procedures (Adams *et al.*, 2013).

2.2.3 Synchronous colonic disease

Synchronous colorectal cancers are present in 2–3% of patients and a further 20% have synchronous significant benign lesions (diverticular disease, colitis or polyps). Synchronous lesions should be diagnosed at colonoscopy or CTC, as this is crucial in planning complete surgical resection. The most distal significant lesion in the colon should be tattooed (Williams *et al.*, 2013) with the proviso that the endoscopist should ensure they are in the sigmoid and not the rectum. The tattoo should be placed into a saline bleb 2–5 cm from the base of the lesion on the distal (anal) side and the estimated distance clearly documented. More than one tattoo may be applied but the endoscopist should document very carefully the number and position of tattoos in relation to the polyp or tumour. Rectal lesions should not be tattooed.

All patients with suspected colonic cancer should be staged with a CT thorax, abdomen and pelvis.

Recommendation grade B

All patients with suspected rectal cancer should be staged with a CT thorax, abdomen and pelvis. Patients being considered for curative locoregional treatment should have MRI of the pelvis.

Recommendation grade B

Synchronous lesions should be identified using colonoscopy or CTC prior to colorectal cancer resection. If complete colonoscopy is not possible, CTC should be considered. CT of the thorax can be combined with CTC to permit staging at the same hospital visit.

Recommendation grade B

2.3 Colorectal Cancer Screening

2.3.1 Screening for average risk population

2.3.1.1 NHS Bowel Cancer Screening Program (BCSP)

The NHS BCSP offers screening every 2 years to the population aged between 60–69, as over 80% of newly diagnosed colorectal cancers occur at this age and beyond. Since 2008, the screening age group has been extended to 74 years old, in accordance with the government's strategy to improve cancer outcomes.

Screening with guaiac faecal occult blood test (FOBT) has been shown to reduce colorectal cancer mortality in four large population-based randomized control trials after more than 10 years of follow up (Table 2.2) (Hewitson *et al.*, 2008). The results from the UK and Denmark were directly comparable. The apparently superior results in the US trial were ascribed to a far higher colonoscopy rate, which in turn was due to more frequent FOB testing and a lower positive test threshold.

The guaiac FOBT is being replaced with the more accurate faecal immunochemical test (FIT) for colorectal cancer screening programs (Halloran *et al.*, 2012). It has shown improved uptake and the ability to detect significantly more colorectal cancers and advanced adenomas (Digby *et al.*, 2016; Moss *et al.*, 2016). However, the higher uptake and test positivity is likely to stretch colonoscopy services even further (Tinmouth *et al.*, 2015).

People with positive faecal occult blood tests (5 or 6 samples tested positive; or 1–4 samples positive, followed by any positive result on two subsequent screening kits) are offered a screening colonoscopy. This is carried out in endoscopy units by a JAG accredited BCSP colonoscopist. For individuals unwilling to have or who cannot tolerate colonoscopy, CTC could be considered. Follow up colonoscopies will be determined by the results of the index colonoscopy.

The NHS BCSP has had a positive impact on elective treatment of colorectal cancers by early cancer detection, increased use of minimally invasive techniques and reducing the need for emergency colorectal

Table 2.2 Characteristics, Relative Risk (RR) and 95% Confidence Interval (CI) for colorectal cancer mortality of 4 randomized controlled trials using FOBT (Hewitson *et al.*, 2008). Yr = Year.

Study	Country	Screening frequency	Age range (Yr)	Follow up period (Yr)	RR	95% CI
Funen	Denmark	Annual	45–75	17	0.84	0.73–0.96
		Biennial			0.89	0.78–1.01
Minnesota	US	Annual	50–80	18	0.67	0.51–0.83
		Biennial			0.79	0.62–0.97
Nottingham	UK	Biennial	45–74	11.7	0.87	0.78–0.97
Goteberg	Sweden	Biennial	60–64	19	0.84	0.71–0.99

cancer resections. It also has had a positive impact on 30-day postoperative mortality and 5-year survival rates.

2.3.1.2 NHS Bowel Scope Program

A randomized controlled trial in the UK has shown that a 'one-off' screening flexible sigmoidoscopy reduces CRC incidence and CRC-related mortality by 23% and 31% respectively (Atkin *et al.*, 2010) after a median follow up of 11 years. Results from the UK trial have prompted the NHS to roll out a population-based program using flexible sigmoidoscopy as screening offered at age 55 with the option to opt in up to aged 60 (<http://www.cancerscreening.nhs.uk/bowel/>).

Population-based NHS Bowel Cancer Screening Program will increase detection of early stage disease, improve cancer survival and reduce the need for emergency surgery. Establishment of flexible sigmoidoscopy screening is likely to reduce incidence of distal cancers as well as reducing mortality.

Recommendation grade A

Patients diagnosed through the National Bowel Cancer Screening Program should have a defined pathway into their local colorectal cancer MDT.

Recommendation grade D

2.3.2 Screening for at risk population

Approximately 5% of colorectal cancers are due to the high-risk familial conditions, Lynch syndrome and the polyposis syndromes. It is important that these familial syndromes are identified so that the index case and family members can be offered appropriate management. In a further 30% there is some familial contribution to aetiology, but the genetic factors involved remain unclear and the level of risk is heterogeneous.

Families deemed to be at high risk of colorectal cancer should be managed through clinical genetic services, which should provide a robust surveillance program ensuring appropriate use of genetic testing, timely surveillance and counseling.

2.3.2.1 Risk stratification according to family history

An accurate family history gives an empirical assessment of risk. The site and age at diagnosis of all cancers in family members should be documented, as well as the presence of related features such as colorectal adenomas. The value of risk assessment on the basis of family history is limited in small families and those with poorly defined paternity. Current BSG guidelines (Cairns *et al.*, 2010) give a detailed evidence base for stratifying risk level according to family history, and provide screening recommendations (summarized in Table 2.3):

Table 2.3 Management of individuals with low, moderate and high risk of CRC.

Risk	Relative risk of CRC	Colonoscopy screening
Low	<2	None
Low moderate	3–6	One off age 55 years
High moderate		5 yearly from 50 years

Low risk

Individuals in this group have one of the following:

- No confirmed family history of colorectal cancer
- No first-degree relative (i.e. parent, sibling or child) with colorectal cancer
- Only one first-degree relative with colorectal cancer, diagnosed at age 50 years or older

Low risk individuals should be reassured, informed of the symptoms of colorectal cancer and encouraged to participate in the NHS Bowel Cancer Screening Program.

Recommendation grade C

Low-moderate risk

This group comprises those with one of:

- One affected relative diagnosed with colorectal cancer under 50 years
- Two affected first-degree relatives diagnosed at age 60 years or older

Low-moderate risk individuals should be offered a 'one-off' screening colonoscopy at the age of 55 years.

Recommendation grade C

High-moderate risk

This group comprises those with one of:

- Three or more relatives with colorectal cancer in a first degree kinship* (but none under 50 years; a factor which confers high risk)
- Two relatives diagnosed with colorectal cancer under 60 years (or with a mean age at diagnosis under 60 years) in a first degree kinship*
- Both parents diagnosed with colorectal cancer under 60 years

*A first-degree kinship is a family group in which each affected individual is a first degree relative of the others. The individual seeking screening should be a first degree relative of one of these affected relatives.

High-moderate risk individuals should be offered colonoscopy every 5 years from the age of 50 to 75 years.

Recommendation grade C

High risk

This category encompasses Lynch syndrome and the polyposis syndromes. Criteria for inclusion include:

- Member of a family with known familial adenomatous polyposis (FAP) or other polyposis syndrome
- Member of a family with known Lynch syndrome
- Pedigree suggestive of autosomal dominantly inherited colorectal (or other Lynch syndrome-associated) cancer (Amsterdam criteria Table 2)
- Pedigree indicative of autosomal recessive inheritance, suggestive of MYH associated polyposis (MAP)

2.3.2.2 Lynch syndrome

This dominantly inherited condition is due to germline mutation in one of the mismatch repair (MMR) genes, and carries a 50–70% lifetime risk of colorectal cancer (often developing at an early age), as well as increased incidence of other cancers. The cancers are characterized by microsatellite instability (MSI) and loss of mismatch repair (MMR) protein, detectable by immunohistochemical staining. There is a preponderance of mucinous and right sided cancers compared to sporadic colorectal cancer populations. Indications for MSI testing are increasing with recent evidence supporting its use in all patients with colorectal cancer (Vasen *et al.*, 2013). Further analysis of methylation status and BRAF mutation can distinguish sporadic cases of MSI from those with a genetic predisposition.

Full guidelines for the management of individuals with Lynch syndrome are available (Vasen *et al.*, 2013), and anyone suspected of having it should be referred to a clinical genetics unit. Important points for the clinician managing these patients are:

- Carcinogenesis is accelerated, mandating colonoscopic screening intervals of no more than 2 years.
- There is evidence that aspirin significantly reduces colorectal cancer risk.
- The risk of metachronous cancer is high, and extended colectomy should be considered instead of segmental colectomy for the treatment of colorectal cancer.
- Prophylactic total abdominal hysterectomy and bilateral salpingo-oophorectomy should be offered to affected women who have reached the end of their reproductive life, especially if they are undergoing surgery for colorectal cancer.

Colonoscopic surveillance for Lynch syndrome mutation carriers should commence at the age of 25 years and continue for every 12–24 months up to the age of 75 years or until co-morbidity makes it clinically inappropriate.

Recommendation grade B

In families manifesting gastric cancer as part of the phenotype, biennial upper gastrointestinal endoscopy should be considered from age of 50 years and continue to age 75 years.

Recommendation grade C

2.3.2.3 Familial adenomatous polyposis (FAP)

This dominantly inherited syndrome is characterized by the development of hundreds of colorectal adenomas from late childhood and results in a risk of colorectal cancer approaching 100% by the age of 50 years. In around 20% of patient with FAP the genetic trait arises from a new mutation. The most important extra-colonic manifestations are duodenal and peri-ampullary adenomas and carcinomas, and desmoid disease.

Full guidelines for the management of individuals with FAP are available (Vasen *et al.*, 2008), and anyone suspected of having it should be referred to a clinical genetics unit or specialist polyposis registry. Important points for the clinician managing these patients are:

- Genetic testing (or endoscopic screening if no mutation has been identified) should begin at around 12 years of age, unless the child is symptomatic.
- Prophylactic surgery is the mainstay of management, the type and timing determined by genotype, phenotype and personal circumstances.
- Lifelong follow-up is required, with annual surveillance of the retained rectum or ileo-anal pouch.
- Endoscopic examination of the duodenum using a side-viewing scope should start at age 30 years and continue at intervals determined by disease severity.

Annual colonoscopy should be offered to mutation carriers from diagnosis until polyp load indicates a need for surgery.

Recommendation grade B

Individuals from families where no mutation can be identified and genetic linkage analysis is not possible, should have annual surveillance from the age of 13–15 until age 30 years, and every 3–5 years thereafter until age 60.

Recommendation grade B

For individuals who have undergone either total colectomy and ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis, lifelong endoscopic annual surveillance of the retained rectum or anorectal cuff is recommended.

Recommendation grade B

Upper gastrointestinal endoscopy (using a side-viewing endoscope) at intervals determined by

Spigelman stage for mutation carriers is recommended from age 30 years.

Recommendation grade C

2.3.2.4 MYH-associated polyposis

This recently recognized polyposis syndrome has considerable overlap with FAP, although the polyp burden is often considerably less, and extra-intestinal manifestations are less frequent (Cairns *et al.*, 2010). Management of the colon and rectum is essentially the same as FAP, although some individuals with a light polyp burden can be managed endoscopically, without the need for prophylactic surgery.

Colonoscopic surveillance is recommended every year from age 25 years for individuals who are bi-allelic MYH carriers (or homozygous carriers of other BER gene defects).

Recommendation grade C

Upper gastrointestinal endoscopy at 3–5 year intervals is recommended from age 30 years.

Recommendation grade C

2.3.2.5 Serrated polyposis

This poorly understood condition is characterized by the development of multiple hyperplastic polyps, sessile serrated polyps and serrated adenomas (Edelstein *et al.*, 2013). There appears to be an inherited element, but the gene(s) responsible have not yet been identified and genetic testing is not available.

Annual surveillance colonoscopy is recommended. First-degree relatives should have five yearly screening from the age of 30 years.

Recommendation grade C

2.3.2.6 Peutz-Jeghers syndrome

This dominantly inherited syndrome results in characteristic gastrointestinal polyps, particularly in the small bowel, and peri-oral pigmentation (Cairns *et al.*, 2010). The risk of gastrointestinal, and other cancers, is substantial. These patients should be referred to a clinical genetics unit or polyposis registry.

A baseline colonoscopy and upper GI endoscopy (OGD) is recommended at age 8 years. If significant polyps are detected, endoscopy should be repeated every 3 years. If no significant polyps are present at baseline endoscopy, routine surveillance is repeated at age 18, or sooner should symptoms arise, and then every 3 years.

Recommendation grade C

Small bowel screening using video capsule endoscopy (VCE) should be performed every 3 years, from age 8 years, or earlier if the patient is symptomatic. Magnetic resonance enterography (MRE) or CT enterography are reasonable alternatives in adult patients but CT enterography is not favoured in children due to radiation exposure.

Recommendation grade C

2.3.2.7 Juvenile polyposis

This is a rare syndrome due to mutation in the *SMAD4* or *BMPRIA* genes, which results in typical polyps, particularly in the large bowel (Cairns *et al.*, 2010). The risk of colorectal cancer is in the range 10–40%, and that of gastric cancer around 25%. Management is usually by endoscopic polypectomy, with surveillance intervals of 1–3 years, depending on polyp burden. Surgery (colectomy, proctocolectomy or gastrectomy) is sometimes required.

Those with a *SMAD4* mutation frequently also have hereditary haemorrhagic telangiectasia, so bleeding or anaemia may not be due to the juvenile polyps, and appropriate investigations to exclude associated arteriovenous malformations should be done before any general anesthetic. These patients should be referred to a clinical genetics unit or polyposis registry.

Colonoscopic surveillance for at risk individuals and mutation carriers is recommended every 1–2 years from age 15–18 years, or earlier if the individual is symptomatic up to age 70 years.

Recommendation grade C

Upper gastrointestinal surveillance is recommended every 1–2 years from age 25 years.

Recommendation grade C

Conflicts of interest

None of the authors have any conflicts of interest to declare.

Acknowledgement

Stuart Taylor is a National Institute for Health Research (NIHR) senior investigator and his work is supported by researchers at the NIHR UCL Hospitals Biomedical Research Centre.

References

- Adams RB, Aloia TA, Loyer E, Pawlik TM, Taouli B, Vauthey JN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. *HPB (Oxford)* 2013; **15**: 91–103.

- Atkin W, Dadswell E, Wooldrage K, Kralj-Hans I, von Wagner C, Edwards R, Yao G, Kay C, Burling D, Faiz O, Teare J, Lilford RJ, Morton D, Wardle J, Halligan S. Computed tomographic colonography versus colonoscopy for investigation of patients with symptoms suggestive of colorectal cancer (SIGGAR): a multicentre randomised trial. *Lancet* 2013; **381**: 1194–202.
- Atkin WS, Edwards R, Kralj-Hans I, Wooldrage K, Hart AR, Northover JM, Parkin DM, Wardle J, Duffy SW, Cuzick J. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. *Lancet* 2010; **375**: 1624–33.
- British Society of Gastrointestinal and Abdominal Radiology (BSGAR), The Royal College of Radiologists. (2014). Guidance on the use of CT colonography for suspected colorectal cancer. <http://www.bsgar.org/standards/rcr-standards/> (accessed 19 May 2017).
- Burling D. CT colonography standards. *Clin Radiol* 2010; **65**: 474–80.
- Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, Evans GD, Eaden JA, Rutter MD, Atkin WP, Saunders BP, Lucassen A, Jenkins P, Fairclough PD, Woodhouse CR. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). *Gut* 2010; **59**: 666–89.
- Digby J, Fraser CG, Carey FA, Diamant RH, Balsitis M, Steele RJ. Faecal haemoglobin concentration is related to detection of advanced colorectal neoplasia in the next screening round. *J Med Screen* 2017; **24**: 62–8.
- Dighe S, Purkayastha S, Swift I, Tekkis PP, Darzi A, A'Hern R, Brown G. Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. *Clin Radiol* 2010; **65**: 708–19.
- Edelstein DL, Axilbund JE, Hyland LM, Romans K, Griffin CA, Cruz-Correa M, Giardiello FM. Serrated polyposis: rapid and relentless development of colorectal neoplasia. *Gut* 2013; **62**: 404–8.
- Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. *Lancet Oncol* 2012; **13**: 1152–60.
- Halligan S, Wooldrage K, Dadswell E, Kralj-Hans I, von Wagner C, Edwards R, Yao G, Kay C, Burling D, Faiz O, Teare J, Lilford RJ, Morton D, Wardle J, Atkin W. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. *Lancet* 2013; **381**: 1185–93.
- Halloran SP, Launoy G, Zappa M. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition—Faecal occult blood testing. *Endoscopy* 2012; **44**(Suppl 3): SE65–87.
- Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol* 2008; **103**: 1541–9.
- McFarland EG, Fletcher JG, Pickhardt P, Dachman A, Yee J, McCollough CH, Macari M, Knechtges P, Zalis M, Barish M, Kim DH, Keysor KJ, Johnson CD. ACR Colon Cancer Committee white paper: status of CT colonography 2009. *J Am Coll Radiol* 2009; **6**: 756–72. e4
- MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. *BMJ* 2006; **333**: 779.
- Moss S, Mathews C, Day TJ, Smith S, Seaman HE, Snowball J, Halloran SP. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. *Gut* 2016; doi:10.1136/gutjnl-2015-310691 [Epub ahead of print]
- National Institute for Health and Clinical Excellence. Suspected cancer: recognition and referral. NICE guideline [NG12], 2015. <https://www.nice.org.uk/guidance/NG12> (accessed 19 May 2017).
- Neri E, Halligan S, Hellstrom M, Lefere P, Mang T, Regge D, Stoker J, Taylor S, Laghi A. The second ESGAR consensus statement on CT colonography. *Eur Radiol* 2013; **23**: 720–9.
- NHS Bowel Cancer Screening Programme. Guidelines for the use of imaging in the NHS Bowel Cancer Screening Programme, 2nd edition, 2012. <http://www.bcspp.nhs.uk/files/nhsbcsp05.pdf> (accessed 19 May 2017).
- Pickhardt PJ, Hassan C, Halligan S, Marmo R. Colorectal cancer: CT colonography and colonoscopy for detection—systematic review and meta-analysis. *Radiology* 2011; **259**: 393–405.
- Smith NJ, Bees N, Barbachano Y, Norman AR, Swift RI, Brown G. Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials. *Br J Cancer* 2007; **96**: 1030–6.
- Tinmouth J, Lansdorp-Vogelaar I, Allison JE. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. *Gut* 2015; **64**: 1327–37.
- Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Moller P, Myrholm T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH, Tejpar S, Thomas HJ, Rahner N, Wijnen JT, Jarvinen HJ, Moslein G. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut* 2013; **62**: 812–23.
- Vasen HF, Moslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bulow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Jarvinen H, Mecklin JP, Moller P, Myrholm T, Nagengast FM, Parc Y, Phillips R, Clark SK, de Leon MP, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen J. Guidelines for the clinical management of familial adenomatous polyposis (FAP). *Gut* 2008; **57**: 704–13.
- Williams JG, Pullan RD, Hill J, Horgan PG, Salmo E, Buchanan GN, Rasheed S, McGee SG, Haboubi N. Management of the malignant colorectal polyp: ACPGBI position statement. *Colorectal Dis* 2013; **15**(Suppl 2): 1–38.